Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure - PubMed (original) (raw)

Review

Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure

Francesco Giorgino et al. Metabolism. 2020 Mar.

Abstract

SGLT-2 inhibitors and most GLP-1 receptor agonists demonstrated cardiovascular superiority and reduction of cardiovascular and overall mortality. These results stand as a turning point in the management of diabetes, shifting the focus from controlling glucose levels to mastering the extra-glycemic effects of these new drugs. This narrative review will discuss recent CVOT with focus on SGLT-2 inhibitors and GLP-1 receptor agonists to distinguish relevant patients' characteristics as potential predictors for therapeutic efficacy. It will also examine their efficacy and safety, the differences in their cardiovascular and renal benefits, aiming to convey clinical suggestions for everyday practice.

Keywords: Cardiovascular; Chronic kidney disease; GLP-1 receptor agonists; Heart failure; SGLT-2 inhibitors.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest F.G.: Research support: Eli Lilly, LifeScan, Takeda Medical Research Foundation. Consultant and author for AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Merck Sharp and Dohme, NovoNordisk, Roche Diabetes Care, Sanofi. M.L.: Research support: Boehringer Ingelheim, MSD, Novo Nordisk, Consultant and author for Boehringer Ingelheim, MSD, Novo Nordisk, Amgen, Sanofi, Astra Zeneca, Bayer and Lilly.

Cited by

Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice.
Lim LL, Chow E, Chan JCN. Lim LL, et al. Nat Rev Endocrinol. 2023 Mar;19(3):151-163. doi: 10.1038/s41574-022-00776-2. Epub 2022 Nov 29. Nat Rev Endocrinol. 2023. PMID: 36446898 Review.
Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update.
Koniari I, Velissaris D, Kounis NG, Koufou E, Artopoulou E, de Gregorio C, Mplani V, Paraskevas T, Tsigkas G, Hung MY, Plotas P, Lambadiari V, Ikonomidis I. Koniari I, et al. J Clin Med. 2022 Aug 9;11(16):4660. doi: 10.3390/jcm11164660. J Clin Med. 2022. PMID: 36012897 Free PMC article. Review.
Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study.
Baviera M, Foresta A, Colacioppo P, Macaluso G, Roncaglioni MC, Tettamanti M, Fortino I, Genovese S, Caruso I, Giorgino F. Baviera M, et al. Cardiovasc Diabetol. 2022 Aug 24;21(1):162. doi: 10.1186/s12933-022-01572-y. Cardiovasc Diabetol. 2022. PMID: 35999556 Free PMC article.
Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies.
Caruso I, Cignarelli A, Sorice GP, Natalicchio A, Perrini S, Laviola L, Giorgino F. Caruso I, et al. Metabolites. 2022 Feb 15;12(2):183. doi: 10.3390/metabo12020183. Metabolites. 2022. PMID: 35208256 Free PMC article. Review.
A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.
Vekic J, Zeljkovic A, Al Rasadi K, Cesur M, Silva-Nunes J, Stoian AP, Rizzo M. Vekic J, et al. Metabolites. 2022 Jan 24;12(2):108. doi: 10.3390/metabo12020108. Metabolites. 2022. PMID: 35208183 Free PMC article. Review.

Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure - PubMed (original) (raw)